Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GSK961081: Phase II started

GSK began a double-blind Phase II trial in about 40 patients

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE